Bo Lak (002760) - Total Liabilities

Latest as of March 2026: ₩9.54 Billion KRW ≈ $6.46 Million USD

Based on the latest financial reports, Bo Lak (002760) has total liabilities worth ₩9.54 Billion KRW (≈ $6.46 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Bo Lak's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Bo Lak - Total Liabilities Trend (2013–2025)

This chart illustrates how Bo Lak's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Bo Lak.

Bo Lak Competitors by Total Liabilities

The table below lists competitors of Bo Lak ranked by their total liabilities.

Company Country Total Liabilities
JCH Systems Inc
KQ:033320
Korea ₩42.00 Billion
Diginex Limited Ordinary Shares
NASDAQ:DGNX
USA $32.01 Million
Laser Photonics Corporation Common Stock
NASDAQ:LASE
USA $11.49 Million
SSC Security Services Corp
V:SECU
Canada CA$22.57 Million
Seres Therapeutics Inc
NASDAQ:MCRB
USA $67.05 Million
Banswara Syntex Limited
NSE:BANSWRAS
India Rs6.85 Billion
Ymc Co. Ltd
KQ:155650
Korea ₩55.40 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Bo Lak's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002760 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.89 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.20 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.16 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Bo Lak's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Bo Lak (2013–2025)

The table below shows the annual total liabilities of Bo Lak from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 ₩10.51 Billion
≈ $7.12 Million
-16.79%
2024-12-31 ₩12.63 Billion
≈ $8.56 Million
+38.06%
2023-12-31 ₩9.15 Billion
≈ $6.20 Million
-26.97%
2022-12-31 ₩12.53 Billion
≈ $8.49 Million
+16.28%
2021-12-31 ₩10.77 Billion
≈ $7.30 Million
+6.60%
2020-12-31 ₩10.11 Billion
≈ $6.85 Million
-13.39%
2019-12-31 ₩11.67 Billion
≈ $7.91 Million
+22.17%
2018-12-31 ₩9.55 Billion
≈ $6.47 Million
+10.95%
2017-12-31 ₩8.61 Billion
≈ $5.83 Million
-17.14%
2016-12-31 ₩10.39 Billion
≈ $7.04 Million
+9.15%
2015-12-31 ₩9.52 Billion
≈ $6.45 Million
-8.14%
2014-12-31 ₩10.36 Billion
≈ $7.02 Million
-0.71%
2013-12-31 ₩10.44 Billion
≈ $7.07 Million
--

About Bo Lak

KO:002760 Korea Specialty Chemicals
Market Cap
$40.19 Million
₩59.30 Billion KRW
Market Cap Rank
#22805 Global
#1498 in Korea
Share Price
₩990.00
Change (1 day)
-1.00%
52-Week Range
₩837.00 - ₩1323.00
All Time High
₩4129.14
About

Bolak Company Limited engages in the manufacture and sale of food ingredients, pharmaceutical raw materials, functional materials, and cosmetic ingredients in South Korea and internationally. The company offers confectionery, beverage, micron, and dairy flavoring products; active pharmaceutical ingredients, such as dry and soft extract powders, fluid extracts, tinctures, natural paclitaxel, docet… Read more